News Releases
|
Financial Results |
|||||||||||||||||||||
| Three Months Ended June 30 | Six Months Ended June 30 | ||||||||||||||||||||
|
|
Increase/ | Increase/ | |||||||||||||||||||
|
(Millions, except per share results) |
2011 | 2010 | (Decrease) | 2011 | 2010 | (Decrease) | |||||||||||||||
| Revenue | $ | 698.3 | $ | 741.7 | (5.9 | )% | $ | 1,391.1 | $ | 1,469.7 | (5.3 | )% | |||||||||
| Segment Profit | 75.9 | 78.5 | (3.3 | )% | 151.7 | 139.9 | 8.4 | % | |||||||||||||
| Net Income | 34.2 | 35.4 | (3.4 | )% | 68.5 | 60.9 | 12.5 | % | |||||||||||||
| Earnings per Share | 1.07 | 1.05 | 1.9 | % | 2.09 | 1.77 | 18.1 | % | |||||||||||||
As of
"Magellan had a strong second quarter, completing a solid first half of the year with results meeting our expectations," said René Lerer, M.D., chairman and chief executive officer. "It's significant that contributions to these results came from across our lines of business, as well as solid care management results from our risk products. Looking ahead, our focus remains on executing our strategy and exploiting our deep experience and clinical expertise. We are particularly enthusiastic about opportunities to bring innovative solutions to new and existing customers in the areas of pharmacy and
"Magellan demonstrated traction during the quarter with existing customers. Our successful partnership with the state of
"I'm pleased with our operational performance during the quarter and our positioning in the marketplace for future growth," said
"Our financial position remains strong, with solid fundamentals and good liquidity," said
2011 Outlook
The company reaffirmed its 2011 guidance ranges for full-year net income of
Earnings Results Conference Call
Management will host a conference call at
About
Cautionary Statement
This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties. All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding estimates of 2011 net income, segment profit, earnings per share, cash flow from operations and strategy. These statements are based on management's analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "may," "should," "could," "estimate," "intend" and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the company's customers to manage the health care services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the company's risk members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in the contracting model for
| MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES | ||||||||||||||||
| CONSOLIDATED STATEMENTS OF INCOME | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2010 |
2011 (1) |
2010 |
2011 (1) |
|||||||||||||
| Net revenue | $ | 741,658 | $ | 698,338 | $ | 1,469,711 | $ | 1,391,093 | ||||||||
| Cost and expenses: | ||||||||||||||||
| Cost of care | 472,478 | 441,446 | 949,157 | 875,146 | ||||||||||||
| Cost of goods sold | 54,771 | 53,404 | 111,067 | 109,923 | ||||||||||||
| Direct service costs and other operating expenses (2) | 139,617 | 131,779 | 277,871 | 263,346 | ||||||||||||
| Depreciation and amortization | 14,235 | 14,267 | 27,657 | 28,219 | ||||||||||||
| Interest expense | 584 | 494 | 1,269 | 965 | ||||||||||||
| Interest income | (803 | ) | (858 | ) | (1,620 | ) | (1,673 | ) | ||||||||
| 680,882 | 640,532 | 1,365,401 | 1,275,926 | |||||||||||||
| Income before income taxes | 60,776 | 57,806 | 104,310 | 115,167 | ||||||||||||
| Provision for income taxes | 25,348 | 23,575 | 43,363 | 46,638 | ||||||||||||
| Net income | 35,428 | 34,231 | 60,947 | 68,529 | ||||||||||||
| Other comprehensive (loss) income | (285 | ) | (19 | ) | (259 | ) | 78 | |||||||||
| Comprehensive income | $ | 35,143 | $ | 34,212 | $ | 60,688 | $ | 68,607 | ||||||||
| Weighted average number of common shares outstanding — basic | 33,323 | 31,301 | 33,849 | 32,171 | ||||||||||||
| Weighted average number of common shares outstanding — diluted | 33,800 | 31,903 | 34,434 | 32,775 | ||||||||||||
| Net income per common share — basic | $ | 1.06 | $ | 1.09 | $ | 1.80 | $ | 2.13 | ||||||||
| Net income per common share — diluted | $ | 1.05 | $ | 1.07 | $ | 1.77 | $ | 2.09 | ||||||||
|
(1) |
For a more detailed discussion of Magellan's results for the quarter ended June 30, 2011, refer to the Company's Quarterly Report on Form 10-Q, which will be filed with the SEC on July 29, 2011, and the live broadcast or taped replay of the Company's earnings conference call on July 29, 2011, which will be available at www.MagellanHealth.com. |
|
|
(2) |
Includes stock compensation expense of $3,706 and $4,205 for the three months ended June 30, 2010 and 2011, respectively, and $8,234 and $8,983 for the six months ended June 30, 2010 and 2011, respectively. |
|
|
|
| MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES | ||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| (Unaudited) | ||||||||
| (In thousands) | ||||||||
| Six Months Ended June 30, | ||||||||
| 2010 |
2011 (1) |
|||||||
| Cash flows from operating activities: | ||||||||
| Net income | $ | 60,947 | $ | 68,529 | ||||
|
Adjustments to reconcile net income to net cash provided by (used in) operating activities: |
||||||||
| Depreciation and amortization | 27,657 | 28,219 | ||||||
| Non-cash interest expense | 361 | 213 | ||||||
| Non-cash stock compensation expense | 8,234 | 8,983 | ||||||
| Non-cash income tax expense | 18,039 | 6,885 | ||||||
|
Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses: |
||||||||
| Restricted cash (2) | 35,956 | 13,697 | ||||||
| Accounts receivable, net | (2,445 | ) | (77,031 | ) | ||||
| Other assets | 5,674 | (21,141 | ) | |||||
| Accounts payable and accrued liabilities | (25,050 | ) | (27,098 | ) | ||||
| Medical claims payable and other medical liabilities | (7,638 | ) | (12,390 | ) | ||||
| Other | 4,454 | 9,246 | ||||||
| Net cash provided by (used in) operating activities | 126,189 | (1,888 | ) | |||||
| Cash flows from investing activities: | ||||||||
| Capital expenditures | (21,681 | ) | (26,693 | ) | ||||
| Acquisitions and investments in businesses, net of cash acquired | - | (274 | ) | |||||
| Purchase of investments | (96,515 | ) | (187,807 | ) | ||||
| Maturity of investments | 84,959 | 123,043 | ||||||
| Net cash used in investing activities | (33,237 | ) | (91,731 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Payments on long-term debt and capital lease obligations | (588 | ) | - | |||||
| Payments to acquire treasury stock | (74,427 | ) | (211,451 | ) | ||||
| Proceeds from issuance of equity | - | 20,000 | ||||||
| Proceeds from exercise of stock options and warrants | 17,148 | 28,842 | ||||||
| Other | (1,504 | ) | 391 | |||||
| Net cash used in financing activities | (59,371 | ) | (162,218 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | 33,581 | (255,837 | ) | |||||
| Cash and cash equivalents at beginning of period | 196,507 | 337,179 | ||||||
| Cash and cash equivalents at end of period | $ | 230,088 | $ | 81,342 | ||||
|
(1) |
The Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 will be filed with the SEC on July 29, 2011. |
|
|
(2) |
Includes the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change. During the six months ended June 30, 2010 and 2011, restricted cash of $662 and $84,077, respectively, was shifted to restricted cash that resulted in an operating cash flow use. |
|
|
|
| MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES | ||||||||||||||||
| CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (In thousands) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2010 | 2011 (1) | 2010 | 2011 (1) | |||||||||||||
| Net revenue | ||||||||||||||||
| - Commercial | $ | 160,982 | $ | 139,686 | $ | 322,684 | $ | 289,721 | ||||||||
| - Public Sector | 368,011 | 362,284 | 717,479 | 712,800 | ||||||||||||
| - Radiology Benefits Management | 105,263 | 90,608 | 214,720 | 179,820 | ||||||||||||
| - Specialty Pharmaceutical Management | 67,993 | 69,366 | 136,131 | 139,596 | ||||||||||||
| - Medicaid Administration (2) | 39,409 | 56,637 | 78,697 | 109,930 | ||||||||||||
| - Elimination (2) | - | (20,243 | ) | - | (40,774 | ) | ||||||||||
| Total net revenue | 741,658 | 698,338 | 1,469,711 | 1,391,093 | ||||||||||||
| Cost of care | ||||||||||||||||
| - Commercial | 90,583 | 79,122 | 181,255 | 154,435 | ||||||||||||
| - Public Sector (2) | 311,609 | 309,934 | 620,671 | 614,855 | ||||||||||||
| - Radiology Benefits Management | 70,286 | 53,828 | 147,231 | 108,545 | ||||||||||||
| - Medicaid Administration | - | 18,805 | - | 38,085 | ||||||||||||
| - Elimination (2) | - | (20,243 | ) | - | (40,774 | ) | ||||||||||
| Total cost of care | 472,478 | 441,446 | 949,157 | 875,146 | ||||||||||||
| Cost of goods sold - Specialty Pharmaceutical Management | 54,771 | 53,404 | 111,067 | 109,923 | ||||||||||||
| Direct service costs and other operating expenses | ||||||||||||||||
| - Commercial | 37,716 | 39,112 | 75,184 | 76,920 | ||||||||||||
| - Public Sector | 15,458 | 16,486 | 33,005 | 33,462 | ||||||||||||
| - Radiology Benefits Management | 15,401 | 15,858 | 30,239 | 32,563 | ||||||||||||
| - Specialty Pharmaceutical Management | 5,922 | 6,083 | 11,473 | 12,095 | ||||||||||||
| - Medicaid Administration | 34,039 | 25,849 | 66,627 | 51,835 | ||||||||||||
| - Corporate | 31,081 | 28,391 | 61,343 | 56,471 | ||||||||||||
| Total direct service costs and other operating expenses | 139,617 | 131,779 | 277,871 | 263,346 | ||||||||||||
| Stock compensation expense (3) | ||||||||||||||||
| - Commercial | (194 | ) | (218 | ) | (432 | ) | (469 | ) | ||||||||
| - Public Sector | (172 | ) | (214 | ) | (373 | ) | (436 | ) | ||||||||
| - Radiology Benefits Management | (368 | ) | (401 | ) | (761 | ) | (883 | ) | ||||||||
| - Specialty Pharmaceutical Management | (114 | ) | (133 | ) | (257 | ) | (259 | ) | ||||||||
| - Medicaid Administration | (22 | ) | (41 | ) | (40 | ) | (64 | ) | ||||||||
| - Corporate | (2,836 | ) | (3,198 | ) | (6,371 | ) | (6,872 | ) | ||||||||
| Total stock compensation expense | (3,706 | ) | (4,205 | ) | (8,234 | ) | (8,983 | ) | ||||||||
| Segment profit (loss) | ||||||||||||||||
| - Commercial | 32,877 | 21,670 | 66,677 | 58,835 | ||||||||||||
| - Public Sector | 41,116 | 36,078 | 64,176 | 64,919 | ||||||||||||
| - Radiology Benefits Management | 19,944 | 21,323 | 38,011 | 39,595 | ||||||||||||
| - Specialty Pharmaceutical Management | 7,414 | 10,012 | 13,848 | 17,837 | ||||||||||||
| - Medicaid Administration | 5,392 | 12,024 | 12,110 | 20,074 | ||||||||||||
| - Corporate and Elimination | (28,245 | ) | (25,193 | ) | (54,972 | ) | (49,599 | ) | ||||||||
| Total segment profit | $ | 78,498 | $ | 75,914 | $ | 139,850 | $ | 151,661 | ||||||||
|
Reconciliation of segment profit to income before income taxes: |
||||||||||||||||
| Segment profit | $ | 78,498 | $ | 75,914 | $ | 139,850 | $ | 151,661 | ||||||||
| Stock compensation expense | (3,706 | ) | (4,205 | ) | (8,234 | ) | (8,983 | ) | ||||||||
| Depreciation and amortization | (14,235 | ) | (14,267 | ) | (27,657 | ) | (28,219 | ) | ||||||||
| Interest expense | (584 | ) | (494 | ) | (1,269 | ) | (965 | ) | ||||||||
| Interest income | 803 | 858 | 1,620 | 1,673 | ||||||||||||
| Income before income taxes | $ | 60,776 | $ | 57,806 | $ | 104,310 | $ | 115,167 | ||||||||
|
(1) |
The Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 will be filed with the SEC on July 29, 2011. |
|
|
(2) |
Effective September 1, 2010, Public Sector has subcontracted with Medicaid Administration to provide pharmacy benefits management services on a risk basis for one of Public Sector's customers. As such, revenue and cost of care related to this intersegment arrangement are eliminated. |
|
|
(3) |
Stock compensation expense is included in direct service costs and other operating expenses; however, this amount is excluded from the computation of segment profit since it is managed on a consolidated basis. |
|
|
|
Media Contact:
David W. Carter, 860-507-1909
dwcarter@magellanhealth.com
or
Investor Contact:
rshapiro@magellanhealth.com
Source:
News Provided by Acquire Media
